Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Intervention | NCT02556632 | Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT02556632', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Curcumin-based Gel)', ' Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.', 'Curcumin-based ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 34ee4f66-e6f7-458c-964c-12fa730a9d56 | |
Comparison | Adverse Events | NCT00087152 | NCT00203502 | the primary trial recorded half as many patients vomiting as the secondary trial. | Contradiction | [
0,
3
] | [
0,
5
] | {'Clinical Trial ID': 'NCT00087152', 'Intervention': ['INTERVENTION 1: ', ' Imatinib Mesylate & Capecitabine', ' Imatinib Mesylate 400 mg by mouth daily for 21 day cycle. Capecitabine 1,000 mg/m^2 by mouth twice daily Days 1-14 of each 21 day cycle.'], 'Eligibility': ['Histologically or cytologically confirmed adenoc... | {'Clinical Trial ID': 'NCT00203502', 'Intervention': ['INTERVENTION 1: ', ' Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', ' Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2', ' + Avastin 15 mg/kg', ' Q 3 weeks X 4 cycles', ' Bevacizumab/Avastin: IV 15mg/kg 21 days', ' Cyclophosphamide: 500mg per meter... | 9b0451fe-f760-46d3-b555-0a9b83546e73 |
Single | Intervention | NCT00021255 | Cohort 2 of the primary trial recieves Doxorubicin only during cycles 1-4, and then Doxorubicin, cyclophosphamide, Herceptin and docetaxel during Cycle 5 of the study. | Contradiction | [
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00021255', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)', ' Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b9304415-073d-476e-a056-cb2a747d56fa | |
Single | Eligibility | NCT00316199 | Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00316199', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Paclitaxel', ' Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression.', ' Paclitaxel: 175 mg/m2, intravenous (IV), every 21 days until disease progression'], 'Eligibility': ['Inclusi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6e365e33-16b8-43e1-99b5-49dfed6f7b13 | |
Single | Intervention | NCT01306942 | Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01306942', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2', ' Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7c2dd3c3-8e72-451e-9fe7-c442f659bfc3 | |
Single | Adverse Events | NCT00656669 | the primary trial recorded 23 adverse events. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00656669', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib Monotherapy', ' Patients who completed the Sunitinib monotherapy segment'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (pri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 27acc6d7-c12d-4a38-9133-a5c8429dd264 | |
Single | Adverse Events | NCT01007942 | There were no adverse event in the primary trial which affected more than 10% of a particular patient cohort. | Contradiction | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT01007942', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Vinorelbine + Trastuzumab', ' Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)', 'INTERVENTION 2: ', ' Pl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5919a080-2f0d-4c3b-9b03-10df80b2e680 | |
Comparison | Eligibility | NCT00671918 | NCT00571987 | Patients with pure ductal carcinoma in situ (DCIS) or Melanoma are eligible for both the secondary trial and the primary trial, and are able to participate in these trials alongside other drug trials, up to a maximum of 3. | Contradiction | [
0,
7,
12
] | [
0,
9
] | {'Clinical Trial ID': 'NCT00671918', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 1.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The pat... | {'Clinical Trial ID': 'NCT00571987', 'Intervention': ['INTERVENTION 1: ', ' Margin Status', ' AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe): Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated... | 91f6e62a-97e7-49fa-8509-7ff8c1f0155e |
Single | Eligibility | NCT01688609 | Patients must have histologically or cytologically confirmed PR+ invasive breast cancer, with Primary tumor > 2 cm in diameter TO PARTICIPATE in the primary trial. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01688609', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Lapatinib, Trastuzumab, Paclitaxel, Surgery)', ' Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b351a091-d5fb-49f9-a864-5c89c6316b1b | |
Comparison | Adverse Events | NCT02139358 | NCT02574455 | There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT02139358', 'Intervention': ['INTERVENTION 1: ', ' Dose Escalation / Phase II Treatment', ' Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.'], 'Eligibility': ['Inclusion Criteria:', ' Adult males or femal... | {'Clinical Trial ID': 'NCT02574455', 'Intervention': ['INTERVENTION 1: ', ' Sacituzumab Govitecan', ' Participants received sacituzumab govitecan 10 mg/kg of body weight, administered as a slow IV infusion either by gravity or with an infusion pump on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. In... | d5ca2086-8404-42d1-bf45-5370f3d4e8e8 |
Comparison | Results | NCT00410813 | NCT00617539 | In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The opposite was true in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00410813', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib, 100 mg, Daily', ' Dasatinib, 100 mg PO daily until progression of disease', 'INTERVENTION 2: ', ' Dasatinib, 70 mg, Twice Daily', ' Dasatinib, 70 mg PO twice daily until progression of disease'], 'Eligibility': ['DISEASE CHARACTE... | {'Clinical Trial ID': 'NCT00617539', 'Intervention': ['INTERVENTION 1: ', ' Irinotecan and Temozolomide', ' irinotecan hydrochloride administered intravenously (IV) at a starting dose of 125 mg/m2 on days 1 and 15 of a 28 day cycle', ' temozolomide orally for seven days at a starting dose of 100 mg/m2 on days 1-7 an... | 4c038972-20a9-4031-a1cd-ba00e9dd0908 |
Comparison | Adverse Events | NCT02132949 | NCT01111825 | Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | {'Clinical Trial ID': 'NCT02132949', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab', ' Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m^2) intravenou... | {'Clinical Trial ID': 'NCT01111825', 'Intervention': ['INTERVENTION 1: ', ' Phase 2 Triple -ve', ' Phase 2, Triple - Negative cohort', 'INTERVENTION 2: ', ' Phase 2 HER2+', ' Phase 2, HER2 - Amplified (HER2-Positive) cohort'], 'Eligibility': ['Inclusion Criteria:', ' Phase I HER2-amplified Cohort', ' HER2 overexp... | 82d6275a-97e6-4d13-84eb-5f7c2585db8b |
Single | Results | NCT01125566 | At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT01125566', 'Intervention': ['INTERVENTION 1: ', ' Afatinib + Vinorelbine (AV)', ' Participants received oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/meter^2 (meter=m) on days 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 286e74e5-74ed-4d42-b32d-f1398c514d37 | |
Comparison | Eligibility | NCT01237327 | NCT00030823 | the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
20,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
51,
54... | {'Clinical Trial ID': 'NCT01237327', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Exemestane 25 milligram (mg) oral tablet taken once daily', 'INTERVENTION 2: ', ' Megestrol Acetate', ' Megestrol acetate 160 mg tablet taken once daily'], 'Eligibility': ['Inclusion Criteria:', ' Previous participation in s... | {'Clinical Trial ID': 'NCT00030823', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of breast ... | 634642da-db6d-49cc-a999-67f46e91dbca |
Single | Eligibility | NCT01401062 | A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial. | Entailment | [
4,
8
] | [] | {'Clinical Trial ID': 'NCT01401062', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Fresolimumab 1 mg/kg)', ' Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a529e364-2da7-4067-acb6-9fb2f0adf08b | |
Single | Eligibility | NCT00004092 | Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from the primary trial. | Entailment | [
4
] | [] | {'Clinical Trial ID': 'NCT00004092', 'Intervention': ['INTERVENTION 1: ', ' Arm I (ACT)', ' Patients receive 41.25 mg/m2 of doxorubicin IV over 24 hours on days -9 to -6, 100 mg/kg of cyclophosphamide IV over 2 hours on day -5, and 725 mg/m2 of paclitaxel IV over 24 hours on day -4. PBSC are reinfused on days -2 and ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 317e00ae-9d17-4f85-8787-602cc2548fdb | |
Comparison | Intervention | NCT00195013 | NCT00620373 | Cohort 2 of the primary trial and the secondary trial are test groups. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00195013', 'Intervention': ['INTERVENTION 1: ', ' Glutamine', ' 10 grams three times a day (orally) for four days and then stop', ' glutamine: 10 grams three times a day (orally) for four days and then stop', 'INTERVENTION 2: ', ' Placebo', ' 10 grams three times a day (orally) for four d... | {'Clinical Trial ID': 'NCT00620373', 'Intervention': ['INTERVENTION 1: ', ' Mammography Only', ' For this reporting arm, the interpretation and analysis was done with mammography only.', 'INTERVENTION 2: ', ' Gamma Imaging', ' For this reporting arm, the interpretation and analysis was done with gamma imaging only.... | de955acc-ce0e-4416-9884-644a06971603 |
Comparison | Intervention | NCT01017549 | NCT01390064 | the secondary trial has more patients cohorts than the primary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01017549', 'Intervention': ['INTERVENTION 1: ', ' Electronic Brachytherapy', ' Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System. Accelerated partial breast irradiation is the method of radiation therapy administration that has been commonly used by physicians using... | {'Clinical Trial ID': 'NCT01390064', 'Intervention': ['INTERVENTION 1: ', ' Initial Cohort', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimoto... | 4956f0d0-4df4-4de3-9a46-6073927485c3 |
Comparison | Eligibility | NCT01985971 | NCT03273426 | Patients will have to undergo an MRI scan for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry. | Entailment | [
0,
6,
2
] | [
0,
6
] | {'Clinical Trial ID': 'NCT01985971', 'Intervention': ['INTERVENTION 1: ', ' EF5 PET/CT Imaging', 'PET/CT Imaging'], 'Eligibility': ['Inclusion Criteria:', ' Subjects with measurable brain metastases of at least 1 cm in any plane based on anatomic imaging.', ' Subjects with prior resection of brain metastases with pr... | {'Clinical Trial ID': 'NCT03273426', 'Intervention': ['INTERVENTION 1: ', ' Core Needle Biopsy', ' Ultrasound-guided core needle biopsy (14G, 5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.', 'INTERVENTION 2: ', ' Vacuum-assisted Biopsy', ' Vacuum-assisted biopsy (10G, 5 core... | 9ca0cc75-58b3-451d-abcc-378526744ca4 |
Single | Eligibility | NCT01581619 | histologically confirmed invasive ductal breast cancer would result in exclusion from the primary trial, but not from the secondary trial. | Contradiction | [
4,
10
] | [] | {'Clinical Trial ID': 'NCT01581619', 'Intervention': ['INTERVENTION 1: ', ' Partial Breast Irradiation', ' Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks', ' External Beam Partial-Breast Irradiation: 40 Gy in ten daily fractions over two weeks'], 'Eligibility': ['Inclusion Criteria:', ' Unicent... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6efb001b-5ed3-470b-a206-7768a1adf597 | |
Single | Intervention | NCT00089973 | the primary trial uses a 3 week cycle for SB-715992 administration. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00089973', 'Intervention': ['INTERVENTION 1: ', ' SB-715992', ' The eligible participants were administered Ispinesib, intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle, at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles, until disease progr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 70dd1a42-6e40-4880-80a8-45dfd4941ce4 | |
Comparison | Intervention | NCT01943916 | NCT01653964 | Not all subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi. | Entailment | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01943916', 'Intervention': ['INTERVENTION 1: ', ' Overall Population', ' Each subject served as her own control, with imaging of each mass by both the test and control modalities. Specificity difference is a single measure for the overall ITD population.'], 'Eligibility': ['Inclusion Criteri... | {'Clinical Trial ID': 'NCT01653964', 'Intervention': ['INTERVENTION 1: ', ' Molecular Breast Imaging', ' Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi.'], 'Eligibility': ['Inclusion Criteria:', ' Subgroup 1, Patients with breast lesions:', ' -At ... | 85f43677-b680-4127-b1da-7e1cc966e4b2 |
Comparison | Eligibility | NCT01783444 | NCT03136367 | Women of any age can participate in the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01783444', 'Intervention': ['INTERVENTION 1: ', ' Everolimus 10 mg + Exemestane 25 mg', ' Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).', 'INTERVENTION 2: ', ' Everolimus 10 mg', ' Everolimus (10 mg daily) (investigational arm).'], 'Eligibility': ['Key Inclusion Cri... | {'Clinical Trial ID': 'NCT03136367', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Option Grid', ' Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.', ' Op... | 4cccea8a-22ae-4813-96df-b902850f4991 |
Single | Adverse Events | NCT00951665 | Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00951665', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib Regimen 1', ' Participants received T-DM1 Q3W + paclitaxel QW intravenously.', 'INTERVENTION 2: ', ' Phase Ib Regimen 2', ' Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.'], 'Eligibility': ['Inclusi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8574ecd7-4da7-49b0-a273-de495bc1fee7 | |
Comparison | Adverse Events | NCT00950300 | NCT00615901 | the primary trial recorded a multitude of patients with chest pain, whereas the secondary trial observed only one patient with abdominal pain. | Contradiction | [
0,
10
] | [
0,
3
] | {'Clinical Trial ID': 'NCT00950300', 'Intervention': ['INTERVENTION 1: ', ' Herceptin IV + Chemotherapy', ' Participants received eight cycles of Herceptin IV plus chemotherapy prior to surgery and ten cycles of Herceptin IV after surgery. Chemotherapy consisted of docetaxel 75 mg/m^2 every 21 days for four cycles fo... | {'Clinical Trial ID': 'NCT00615901', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (CMF at 14 Day Intervals)', ' This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A... | 01b82c51-dd3d-430b-9523-0e93a9eb9c1a |
Single | Adverse Events | NCT00451555 | Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00451555', 'Intervention': ['INTERVENTION 1: ', ' Enzastaurin + Fulvestrant QD + BID', ' Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.', ' Participants received enzastaurin loadi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 93149dfc-667b-48d3-a46d-ad48b15e701f | |
Single | Intervention | NCT01422408 | the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01422408', 'Intervention': ['INTERVENTION 1: ', ' Supportive Care (Fluocinonide Cream)', ' This is a single-arm, single-stage, open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms.', ' All subjects will receive topical fluocinonide 0.05% cream to apply t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d080eec7-412f-4a44-8c56-91e0ec459acc | |
Comparison | Intervention | NCT00659373 | NCT02202252 | the primary trial has a 5 year long intervention, the duration of the secondary trial is only a single day after removal of the drains. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
5,
10,
5
] | {'Clinical Trial ID': 'NCT00659373', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen', ' Tamoxifen 20mg orally daily for 5 years', 'INTERVENTION 2: ', ' Ovarian Function Suppression', ' Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH... | {'Clinical Trial ID': 'NCT02202252', 'Intervention': ['INTERVENTION 1: ', ' Single Drain', ' Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.', ' Ultrasonography after removal of the drains: One day after removal of the dr... | fd18a599-f94a-478a-975f-854a4210ccad |
Comparison | Intervention | NCT01797120 | NCT02005887 | the secondary trial and the primary trial both have a placebo arm and a test arm. | Contradiction | [
7,
8,
9,
3,
4,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT01797120', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant & Everolimus', ' Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.', ' Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1... | {'Clinical Trial ID': 'NCT02005887', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Triptorelin + Letrozol', ' Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles', ' Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycle... | ac9ca070-80b2-4913-97d8-06d1b90fcfce |
Single | Intervention | NCT00082810 | Throughout the duration of the primary trial, pariticpants receive increasing doses of Fulvestrant. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00082810', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg + Tipifarnib 300 mg', ' Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 19f5ff0d-3419-4f27-a7e5-6c7291c3cd21 | |
Single | Eligibility | NCT00479674 | Patients that have previously been trated with bevacizumab are not eligible for the primary trial. | Entailment | [
22,
24
] | [] | {'Clinical Trial ID': 'NCT00479674', 'Intervention': ['INTERVENTION 1: ', ' Abraxane, Carboplatin, Bevacizumab', ' Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15', ' Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 009d23bb-2179-4ce3-927d-4dedca6b32a8 | |
Comparison | Results | NCT00577122 | NCT01923168 | the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00577122', 'Intervention': ['INTERVENTION 1: ', ' Cohort I: MPA-Alone', ' Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.', 'INTERVENTION 2: ', ' Cohort 2: MPA+IdoCM', ' Medroxyprogesterone progesterone acetate (MPA) will be administered o... | {'Clinical Trial ID': 'NCT01923168', 'Intervention': ['INTERVENTION 1: ', ' Alpelisib + Letrozole', ' Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.', 'INTERVENTION 2: ', ' Placebo + Letrozole', ' Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg o... | 5152d810-7669-4fb2-a66b-a0a1d6026af5 |
Single | Eligibility | NCT02005549 | Patients with stage 3 Cervical carcinoma are excluded from the primary trial. | Entailment | [
0,
3
] | [] | {'Clinical Trial ID': 'NCT02005549', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab+Docetaxel+Capecitabine', ' Participants received bevacizumab, 15 mg/kg IV, followed by docetaxel 75 mg/m^2 IV on Day 1 and capecitabine 950 mg/m^2 PO BID within 30 minutes after the end of a meal, starting the evening of Day 1 and... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e8f4a600-0296-47d4-903b-2fa840ebcf28 | |
Single | Results | NCT02069093 | 2 of the patients in the primary trial were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT02069093', 'Intervention': ['INTERVENTION 1: ', ' Dexamethasone Based Mouthwash', ' Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or dri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3fa8b747-b48d-4fb4-995d-38a23c64ccb3 | |
Comparison | Intervention | NCT03167359 | NCT01385137 | Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT03167359', 'Intervention': ['INTERVENTION 1: ', ' Participants With Stage 0-III Breast Cancer', ' Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.', ' Hypofractionated Simultane... | {'Clinical Trial ID': 'NCT01385137', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3-fatty Acid)', ' Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Pa... | b9c294c3-93b7-4681-be02-285f9e5cd867 |
Single | Intervention | NCT00322374 | Cohort 2 of the primary trial receive a higher dose of Ixabepilone, at a higher frequency, than cohort 1, | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00322374', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2', ' Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.', 'INTERVENTION 2: ', ' Ixabepilone 30 mg^m2 + E... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9df90d78-d857-4e1d-a650-e47f7b6b68d6 | |
Single | Results | NCT03098550 | There results section indicates there were no patients in the primary trial with 0 adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT03098550', 'Intervention': ['INTERVENTION 1: ', ' Nivolumab + Daratumumab (TNBC)', ' Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe | |
Comparison | Intervention | NCT01653964 | NCT02660788 | The interventions in the primary trial and the secondary trial are so different that it is not possible or useful to compare them. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT01653964', 'Intervention': ['INTERVENTION 1: ', ' Molecular Breast Imaging', ' Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi.'], 'Eligibility': ['Inclusion Criteria:', ' Subgroup 1, Patients with breast lesions:', ' -At ... | {'Clinical Trial ID': 'NCT02660788', 'Intervention': ['INTERVENTION 1: ', ' Control Arm', ' Mail', ' Standard Reminder Postcard', 'INTERVENTION 2: ', ' Family Physician Reminder Letter Arm', ' Mail', ' Standard Reminder Postcard', ' Family Physician Reminder Letter'], 'Eligibility': ['Inclusion Criteria:', ' Ac... | 92ac6e0c-8427-454d-9218-36eda1c580a7 |
Single | Results | NCT00733408 | There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00733408', 'Intervention': ['INTERVENTION 1: ', ' Tx (Chemo, MoAb, and Enzyme Inhibitor)', ' INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 d... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f0aff1fc-4a67-4b28-a974-a4a67a5c930f | |
Comparison | Eligibility | NCT00121836 | NCT00256243 | Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
11
] | {'Clinical Trial ID': 'NCT00121836', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev', ' First Study Treatment Phase:', ' Capecitabine 1000 mg/m² oral (PO) twice-daily, Days 1-15 of each 3-week cycle (28 doses per cycle); bevacizumab 15 mg/kg intravenous (IV) inf... | {'Clinical Trial ID': 'NCT00256243', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy With GM-CSF', ' Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6) This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (C... | 2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6 |
Single | Results | NCT00684983 | The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00684983', 'Intervention': ['INTERVENTION 1: ', ' Arm A', ' Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. lapatinib ditosylate: Gi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 96ab702d-cfe1-48fb-b348-a7c7b8db3f16 | |
Single | Adverse Events | NCT00811135 | The majority of patients in the primary trial experienced at least one adverse event. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00811135', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Bevacizumab + Capecitabine', ' Participants received IV trastuzumab (8 mg/kg) for first cycle and then 6 mg/kg for subsequent cycles followed by bevacizumab (15 mg/kg) on Day 1 of each treatment cycles along with capecitabine ad... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6224d2de-c62b-4b43-8517-475eaa565491 | |
Comparison | Adverse Events | NCT01095003 | NCT01702571 | In total more than 5 patients in the primary trial and the secondary trial experienced Earache. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT01095003', 'Intervention': ['INTERVENTION 1: ', ' Vinflunine Plus Capecitabine', ' Vinflunine plus Capecitabine: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks', ' Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day... | {'Clinical Trial ID': 'NCT01702571', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine (All Participants)', ' This cohort (Cohort 1) enrolled all participants with HER2 positive, unresectable, LABC or mBC who had received prior anti-HER2 and chemotherapy treatment and had progressed on or after the most re... | 95154c62-9f79-4d80-90fd-2f61612285b0 |
Comparison | Adverse Events | NCT00721630 | NCT00364611 | the primary trial and the secondary trial recorded the exact same number of cases of nausea. | Entailment | [
0,
4
] | [
0,
7
] | {'Clinical Trial ID': 'NCT00721630', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Lapatinib', ' The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.', ' capecitabine, lapatinib: Capecitabine 2,000mg twice daily for 7... | {'Clinical Trial ID': 'NCT00364611', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and Bevacizumab', ' Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxici... | 2f6243a9-af40-426d-9a6a-a5c5708cf1b4 |
Single | Eligibility | NCT00058058 | Candidates for the primary trial do not need to meet a specific life expectancy criteria. | Entailment | [
19,
9
] | [] | {'Clinical Trial ID': 'NCT00058058', 'Intervention': ['INTERVENTION 1: ', ' Reference Standard Positive (RS+)', ' Reference Standard Positive indicates a breast cancer diagnosed in the contralateral (study) breast. Participants who received a diagnosis of ductal carcinoma in situ or any invasive breast cancer as a re... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 837f0588-22fc-4069-b2bc-297b3f6aabf7 | |
Comparison | Intervention | NCT00572728 | NCT02472964 | Patients in the primary trial will not be made to take Herceptin© (trastuzumab) or paclitaxel intravenously like those in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00572728', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic (18F-FLT)', ' Patients undergo 18F-FLT PET/CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery,... | {'Clinical Trial ID': 'NCT02472964', 'Intervention': ['INTERVENTION 1: ', ' Herceptin© + Taxane', ' Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint... | 01ef1af2-bac4-4ff9-9f0e-bb39276a9d78 |
Single | Eligibility | NCT03511378 | Patients must have a life expectancy over half a year to participate in the primary trial. | Entailment | [
0,
8
] | [] | {'Clinical Trial ID': 'NCT03511378', 'Intervention': ['INTERVENTION 1: ', " Lupin's Pegfilgrastim", ' 6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.', " Lupin's Pegfilgrastim: Administration of Pegfilgrastim", 'INTERVENTION 2: ', ' Neulasta®', ' 6 mg, subcutaneous injection ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e7b47e19-9cd0-4121-a79a-ee223e7f3ab7 | |
Single | Adverse Events | NCT02630693 | A 30% of patients in the primary trial suffered a life-threatening reaction to an infection. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT02630693', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib (100mg)', ' Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules', ' Palbociclib 100mg: 100mg PO daily', ' Fulvestrant or Tamoxifen or Aromatase Inhibitor: given... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 21cf4dfe-2cd7-4e60-943d-2f7e1266a80d | |
Comparison | Adverse Events | NCT00679341 | NCT00201851 | The only adverse event observed in Patients from both the secondary trial and the primary trial, was Endocervical cancer. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00679341', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.', 'INTERVENTION 2: ', ' Trastuzumab + Docetaxel', ' Patients receive... | {'Clinical Trial ID': 'NCT00201851', 'Intervention': ['INTERVENTION 1: ', ' A - Scheduled Surgery', ' Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen', ' Tamoxifen: 20 mg po daily x 5 years', ' Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 ... | d72ecaae-c132-480c-af5e-87c58dd26082 |
Comparison | Eligibility | NCT00721409 | NCT02413320 | Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00721409', 'Intervention': ['INTERVENTION 1: ', ' Phase 1 (Palbociclib + Letrozole)', ' In Cycle 1 (3 weeks), participants received single agent palbociclib 125 mg/d orally for 2 weeks followed by 1 week off treatment. In Cycles 2 and beyond (4 weeks each), participants received letrozole 2.... | {'Clinical Trial ID': 'NCT02413320', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin + Paclitaxel Then Doxorubicin + Cyclophosphamide', ' Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (60... | 80245791-4a95-4682-bd5f-856694c9f52f |
Comparison | Eligibility | NCT01325428 | NCT00073073 | the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT01325428', 'Intervention': ['INTERVENTION 1: ', ' Part A: Afatinib Once Daily (OD).', ' Part A: Patients received Afatinib tablets, 40 mg taken orally Once Daily (OD) until PD. In case of treatment-related AEs, the 40 mg dose could be reduced by increments of 10 mg to 30 mg once daily or 20 ... | {'Clinical Trial ID': 'NCT00073073', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended... | be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138 |
Single | Intervention | NCT01923168 | Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01923168', 'Intervention': ['INTERVENTION 1: ', ' Alpelisib + Letrozole', ' Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.', 'INTERVENTION 2: ', ' Placebo + Letrozole', ' Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f0da58e6-e937-41ac-b53a-d46ec8a28d11 | |
Comparison | Intervention | NCT02685566 | NCT03076190 | the primary trial and the secondary trial have the same number of study groups, and are both testing the effectiveness of Full-Field Digital Mammography. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02685566', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System.', ' This endpoint will be evaluated qualitatively. The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in can... | {'Clinical Trial ID': 'NCT03076190', 'Intervention': ['INTERVENTION 1: ', ' Active Control Group', ' Health Education Active Control Group', 'INTERVENTION 2: ', ' My Surgical Success Treatment Group', ' My Surgical Success Intervention Group'], 'Eligibility': ['Inclusion Criteria:', ' Age 18+', ' Scheduled for br... | 5a74a63a-3912-44f0-9e83-4e6b678cbe90 |
Single | Eligibility | NCT00325234 | Patients under the age of 18, wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment prior to study entry, and have a life expectancy of more than 3 months. | Contradiction | [
0,
7,
8,
13
] | [] | {'Clinical Trial ID': 'NCT00325234', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed/Carboplatin', ' Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1. Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consisten... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 43f03ba4-ef03-4f57-b059-3d9267f0dcf8 | |
Single | Eligibility | NCT02413320 | Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for the primary trial. | Entailment | [
0,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02413320', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin + Paclitaxel Then Doxorubicin + Cyclophosphamide', ' Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (60... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6e106caf-2522-4022-898d-64b82093d77a | |
Single | Intervention | NCT00021255 | Cohort 2 of the primary trial recieves Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study. | Entailment | [
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00021255', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)', ' Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7f8a918c-fab8-4129-8178-0cda7d0441e1 | |
Single | Results | NCT01125566 | At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT01125566', 'Intervention': ['INTERVENTION 1: ', ' Afatinib + Vinorelbine (AV)', ' Participants received oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/meter^2 (meter=m) on days 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 84aa1194-c081-4acf-9ed6-8cf0d1a08f5d | |
Comparison | Eligibility | NCT02018458 | NCT00895414 | Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial. | Contradiction | [
25,
28
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | {'Clinical Trial ID': 'NCT02018458', 'Intervention': ['INTERVENTION 1: ', ' LA TNBC: DC Vaccine+Preop Chemo', ' LA TNBC patients will be enrolled to receive DC vaccinations during the 24 weeks of standard preoperative dose-dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel and carboplatin (TCb) chemothera... | {'Clinical Trial ID': 'NCT00895414', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin Hydrochloride Alone', ' Participants who received doxorubicin hydrochloride alone in either Cycle 1 or Cycle 2.', 'INTERVENTION 2: ', ' Doxorubicin Hydrochloride With Enalapril', ' Participants who received doxorubicin hydrochlo... | 2bd65df6-4f1d-461c-93f5-f2ddbfde57b6 |
Single | Eligibility | NCT02550210 | Patients must have ductal carcinoma, that can be felt by touch to be eligible for the primary trial. | Contradiction | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT02550210', 'Intervention': ['INTERVENTION 1: ', ' Breast Cancer Locator (BCL)', ' The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0290bc2d-9cd3-44ab-9b04-385f19527c42 | |
Comparison | Results | NCT00577122 | NCT01923168 | the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00577122', 'Intervention': ['INTERVENTION 1: ', ' Cohort I: MPA-Alone', ' Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.', 'INTERVENTION 2: ', ' Cohort 2: MPA+IdoCM', ' Medroxyprogesterone progesterone acetate (MPA) will be administered o... | {'Clinical Trial ID': 'NCT01923168', 'Intervention': ['INTERVENTION 1: ', ' Alpelisib + Letrozole', ' Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.', 'INTERVENTION 2: ', ' Placebo + Letrozole', ' Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg o... | 505afbf8-b2b4-4b12-99c5-e0feef473248 |
Comparison | Eligibility | NCT01816594 | NCT02222337 | Patients with histologically confirmed, newly diagnosed stage 0 bilateral breast cancer cannot take part in the primary trial, but may still be eligible for the secondary trial. | Entailment | [
11
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01816594', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + BKM120 + Paclitaxel', ' BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.', 'INTERVENTION 2: ', ' Trastuzumab + BKM120 PBO + Paclitaxel', ' BKM120 placebo in combination with trastuzumab... | {'Clinical Trial ID': 'NCT02222337', 'Intervention': ['INTERVENTION 1: ', ' Usual Care Survivors', ' Survivors randomized to usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family ther... | 19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5 |
Comparison | Intervention | NCT01830933 | NCT01224678 | Patients in the primary trial and the secondary trial are administered daily oral medication. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
5
] | {'Clinical Trial ID': 'NCT01830933', 'Intervention': ['INTERVENTION 1: ', ' Usual Care', ' Usual Care is the comparison Clinic Patients, where there is no change in their standard or usual care.', 'INTERVENTION 2: ', ' BreastCARE Intervention', ' Intervention Clinic Patients: The participants will answer questions ... | {'Clinical Trial ID': 'NCT01224678', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Patients receive oral placebo once daily for 12 months.', 'INTERVENTION 2: ', ' Vitamin D', ' Patients receive oral vitamin D (2000 IU) once daily for 12 months.'], 'Eligibility': ['Premenopausal women 55 years of age or younger... | 2e540abd-06e3-483d-bd69-6eb5d2275e9e |
Single | Adverse Events | NCT00274469 | No less than 2 patients from either cohorts of the primary trial felt nauseous. | Contradiction | [
0,
12,
13,
25
] | [] | {'Clinical Trial ID': 'NCT00274469', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 500 mg', 'Fulvestrant 500 mg', 'INTERVENTION 2: ', ' Anastrozole 1 mg', 'Anastrozole 1 mg'], 'Eligibility': ['Inclusion Criteria:', ' Confirmed hormone receptor positive advanced breast cancer, postmenopausal women', 'Exclusion C... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d905f4cb-32aa-41b8-8f61-40578d8ea9ae | |
Single | Adverse Events | NCT00232505 | There were 2 instances of patients with Atrial tachycardia in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00232505', 'Intervention': ['INTERVENTION 1: ', ' Cetuximab', ' Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.', ' c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 45510043-7931-493b-8251-41b0be9aabbd | |
Single | Adverse Events | NCT00193037 | 10 of the patients in Cohort 1 of the primary trial suffered from Hypotension. | Contradiction | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT00193037', 'Intervention': ['INTERVENTION 1: ', ' Arm A -Liposomal Doxorubicin Then Docetaxel', ' Liposomal doxorubicin (Arm A)', ' Liposomal doxorubicin 40 mg/m2 IV day 1 over one hour, repeated q 28 days thru peripheral vein or central venous access. This will define one cycle.', ' Patie... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e7037f34-bd2e-402e-a19c-48073781885a | |
Single | Eligibility | NCT00981305 | Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as long as they are over the age of 20. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00981305', 'Intervention': ['INTERVENTION 1: ', ' Lactate-containing Vaginal Lubricant', ' apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)', ' Lactate-containing vaginal lubricant: vaginal applying at least 3cc of ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5275a332-46c1-4941-8850-26a8033012e3 | |
Comparison | Intervention | NCT01129622 | NCT01156987 | the secondary trial and the primary trial both used MRI and Letrozole for their interventions. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01129622', 'Intervention': ['INTERVENTION 1: ', ' Letrozole, Breast Enhancement, Safety', ' Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment). Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI.'], 'Eligibili... | {'Clinical Trial ID': 'NCT01156987', 'Intervention': ['INTERVENTION 1: ', ' Healthy Volunteers', ' Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.', ' Magnetic resonance imaging: Patients and healthy volunteers will be... | 1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0 |
Single | Eligibility | NCT01004744 | Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial. | Entailment | [
2
] | [] | {'Clinical Trial ID': 'NCT01004744', 'Intervention': ['INTERVENTION 1: ', ' Presurgical Oral Anastrozole', ' 1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.', ' Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery'], 'Eligibility': ['Inclusion Cri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b02f43d7-44bb-4219-9a08-fd70e7cc9b87 | |
Single | Eligibility | NCT01827163 | Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial. | Entailment | [
13,
14
] | [] | {'Clinical Trial ID': 'NCT01827163', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel With Trastuzumab and Lapatinib', " Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegf... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1a6661e0-343f-4056-b568-611e7cc7750c | |
Comparison | Intervention | NCT03196635 | NCT01943916 | the primary trial and the secondary trial are both evaluating patient assisted imaging interventions. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03196635', 'Intervention': ['INTERVENTION 1: ', ' All Study Participants, PA Compression Image Sets', ' All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers.', 'INTERVENTION 2: ', ' All Study Partic... | {'Clinical Trial ID': 'NCT01943916', 'Intervention': ['INTERVENTION 1: ', ' Overall Population', ' Each subject served as her own control, with imaging of each mass by both the test and control modalities. Specificity difference is a single measure for the overall ITD population.'], 'Eligibility': ['Inclusion Criteri... | ec97c90e-f904-4cf2-9567-8525edf747cf |
Comparison | Intervention | NCT00820222 | NCT01819233 | the secondary trial and the primary trial do not test the same modalities of cancer treatments. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00820222', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib Plus Capecitabine', ' Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also r... | {'Clinical Trial ID': 'NCT01819233', 'Intervention': ['INTERVENTION 1: ', ' Behavioral Dietary Intervention', ' Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric inta... | 7a129a1e-20d9-4f5a-a921-d30957460e27 |
Single | Results | NCT01566721 | The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01566721', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: SC Herceptin by Needle/Syringe', ' Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by n... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4 | |
Comparison | Adverse Events | NCT03176238 | NCT01498458 | Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03176238', 'Intervention': ['INTERVENTION 1: ', ' Asian Everolimus + Exemestane', ' Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily. Participants in Asian countries: Indonesia, India, Vietnam, Turkey, South Korea, Thailand, Malaysia, Taiwan or Jordan.... | {'Clinical Trial ID': 'NCT01498458', 'Intervention': ['INTERVENTION 1: ', ' Pazopanib Plus Capecitabine', ' A maximal tolerated dose (MTD) could not be established. The study was stopped after 8 patients.'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent for all study procedures according to local... | a1c99d5b-d53a-4195-ad5f-5e1b48c22078 |
Single | Eligibility | NCT00331630 | Men with Left ventricular ejection fraction > 50% are excluded from participating in the primary trial. | Contradiction | [
18,
9
] | [] | {'Clinical Trial ID': 'NCT00331630', 'Intervention': ['INTERVENTION 1: ', ' Treatment With Lapatinib and Abraxane', ' 30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0203435e-03a0-4c41-afdf-6c497d8908c1 | |
Comparison | Adverse Events | NCT00083174 | NCT00190671 | The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT00083174', 'Intervention': ['INTERVENTION 1: ', ' Open-label Extension: Exemestane', ' one 25 mg tablet daily in am', ' exemestane: one 25 mg tablet daily in am'], 'Eligibility': ['At increased risk of developing breast cancer, due to at least one of the following risk factors:', ' Gail sc... | {'Clinical Trial ID': 'NCT00190671', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed 600mg/m2', ' Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles', 'INTERVENTION 2: ', ' Pemetrexed 1800mg/m2', ' Pemetrexed: 1800 mg/m2, intravenous, ev... | e6388dc2-b096-467d-8b70-fd5346dd581a |
Comparison | Intervention | NCT00429182 | NCT00429507 | the secondary trial exclusively uses radiotherapy in its intervention, whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00429182', 'Intervention': ['INTERVENTION 1: ', ' High-dose Chemotherapy', ' Carboplatin + Cyclophosphamide + Thiotepa', ' Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.', ' Thiotepa : 120 mg/m^2 by vein days -6... | {'Clinical Trial ID': 'NCT00429507', 'Intervention': ['INTERVENTION 1: ', ' Samarium 153-EDTMP + Stem Cell Transplant', ' Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones, receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose. Stem Cell Transplant D... | 93511e52-1c12-4dee-858e-13b10793e2a6 |
Single | Eligibility | NCT02005549 | Patients with Cervical carcinoma in situ are excluded from the primary trial. | Contradiction | [
0,
3
] | [] | {'Clinical Trial ID': 'NCT02005549', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab+Docetaxel+Capecitabine', ' Participants received bevacizumab, 15 mg/kg IV, followed by docetaxel 75 mg/m^2 IV on Day 1 and capecitabine 950 mg/m^2 PO BID within 30 minutes after the end of a meal, starting the evening of Day 1 and... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cb932dbf-4c98-4488-b189-1286442968b6 | |
Single | Adverse Events | NCT00545688 | There were no patients with paranasal sinus reactions in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00545688', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab+Docetaxel', ' Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg on Day 1 of Cycles 2-4 an... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0b9aa7e8-5912-44db-b9b0-6a84df769e19 | |
Single | Eligibility | NCT00756717 | Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00756717', 'Intervention': ['INTERVENTION 1: ', ' MK-0752', ' Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days', ' MK-0752: Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day fo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 570ab6bb-b23c-4955-b6b0-d756d1b69c0e | |
Single | Intervention | NCT00296036 | the primary trial administers the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00296036', 'Intervention': ['INTERVENTION 1: ', ' Urea/Lactic Acid Cream', ' Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily.', 'INTERVENTION 2: ', ' Placebo Cream', ' Patients receive placebo cream applied to palms and soles twice daily.'], 'El... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | daf105f8-58e8-47d7-b0a2-5949620b0a2b | |
Single | Eligibility | NCT01582971 | In order to participate in the primary trial, participants must be aware of where they are, and what day it is. | Entailment | [
0,
8
] | [] | {'Clinical Trial ID': 'NCT01582971', 'Intervention': ['INTERVENTION 1: ', ' Week 5 Intervention Group', ' Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member.', ' Friend/family member was trained in foot reflexology protocol by certified reflexologist.', ' Friend/family member provides... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c4b671ae-4701-43a3-ada1-659c265d1f3a | |
Single | Adverse Events | NCT00717405 | There was a dental adverse event in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00717405', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Trastuzumab', ' Neoadjuvant treatment (Cycles 1-8, 3-week cycle): Participants received 15 mg/kg IV bevacizumab q3w for 8 cycles, 4 cycles of 500 mg/m^2 IV 5-fluorouracil, 100 mg/m^2 IV epirubicin, and 500 mg/m^2 IV cyclophospha... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0a17a404-ed1d-4c31-a192-509b68198ea8 | |
Comparison | Intervention | NCT02699983 | NCT00994279 | Neither the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT02699983', 'Intervention': ['INTERVENTION 1: ', ' Group I (SparkPeople Program)', ' Participants receive training on how to use the SparkPeople website, self-monitor their diet using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.', ' Parti... | {'Clinical Trial ID': 'NCT00994279', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Yoga Intervention', ' Yoga Intervention', ' Yoga: Yoga sessions', 'INTERVENTION 2: ', ' Arm 2: Educational Wellness Group', ' Educational Wellness Group', ' Education: Educational Wellness Group'], 'Eligibility': ['Inclusion Criter... | 9661db11-0c91-48c6-a8e8-6cb7cc2b06fd |
Comparison | Intervention | NCT02115607 | NCT01823107 | Patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02115607', 'Intervention': ['INTERVENTION 1: ', ' Definity Infusion', ' Infusion of Definity (Perflutren Lipid Microspheres)', ' Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min'], 'Eligibility': ['Inc... | {'Clinical Trial ID': 'NCT01823107', 'Intervention': ['INTERVENTION 1: ', ' Meso BioMatrix Acellular Peritoneum Matrix', ' All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander... | e8b86ef4-3ce8-4d81-a632-f30672c80ff5 |
Single | Intervention | NCT00146172 | Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of LA-EP2006. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00146172', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 40 mg', 'Neratinb 40 mg qd', 'INTERVENTION 2: ', ' Neratinib 80 mg', 'Neratinib 80 mg qd'], 'Eligibility': ['Inclusion Criteria:', ' Her2/neu or Her1/EGFR positive cancer', ' Eastern Cooperative Oncology Group (ECOG) performance s... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 879f2f14-38a8-419a-bae0-e62ed81eb9dd | |
Comparison | Adverse Events | NCT01752907 | NCT01940497 | There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01752907', 'Intervention': ['INTERVENTION 1: ', ' General Education DVD', ' Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a general chemotherapy side eff... | {'Clinical Trial ID': 'NCT01940497', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab (Vial): Adjuvant', ' Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] ... | 2ec46285-dd0c-4420-b9f6-e44a1ac74f20 |
Single | Eligibility | NCT00121992 | In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-4, N1 and M1 bilateral breast cancer. | Contradiction | [
12,
13,
14,
15,
19
] | [] | {'Clinical Trial ID': 'NCT00121992', 'Intervention': ['INTERVENTION 1: ', ' Arm A: FAC', ' FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv', ' 5-fluorouracil', ' Doxorubicin', 'Cycl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f8afffdc-649b-4921-942a-66b804a3717f | |
Single | Results | NCT01806259 | In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT01806259', 'Intervention': ['INTERVENTION 1: ', ' Ketorolac 30 mg', ' Active drug to be compared with placebo', 'Ketorolac 30 mg IV', 'INTERVENTION 2: ', ' NaCl 0.9% 3mL', 'Ketorolac 30 mg IV'], 'Eligibility': ['Inclusion Criteria:', ' Written informed Consent age : 18-85 years weight: 50-... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 65f22210-47dd-4865-99e2-ddd414dddb08 | |
Comparison | Eligibility | NCT00915603 | NCT02511730 | INR of 1.35 is enough for participation in the primary trial and the secondary trial. | Contradiction | [
0,
24
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00915603', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel/Bevacizumab/Everolimus', 'Systemic Therapy', 'INTERVENTION 2: ', ' Paclitaxel/Bevacizumab/Placebo', 'Systemic Therapy'], 'Eligibility': ['Inclusion Criteria:', ' Female or male patients >=18 years of age.', ' Histologically confi... | {'Clinical Trial ID': 'NCT02511730', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT', ' FFDM Plus DBT: Fujifilm Aspire Cristalle System', 'INTERVENTION 2: ', ' FFDM', ' Breast Images with FFDM alone', ' FFDM: Fujifilm Aspire Cristalle System'], 'Eligibility': ['Inclusion ... | ff8a1e0d-d2ee-4687-b429-5b3b6081edc6 |
Single | Adverse Events | NCT00917735 | One patient in cohort 2 of the primary trial crashed their motorbike. | Entailment | [
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00917735', 'Intervention': ['INTERVENTION 1: ', ' Green Tea Extract', ' Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg cat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b86f0f3c-7905-470d-ae5d-e1867eb8bd3b | |
Single | Adverse Events | NCT01560416 | There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial. | Contradiction | [
0,
1,
12,
13
] | [] | {'Clinical Trial ID': 'NCT01560416', 'Intervention': ['INTERVENTION 1: ', ' ARM A - Fulvestrant', ' Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0aa3c085-b9c6-4918-a5d0-eabc55bdd177 | |
Single | Adverse Events | NCT00828074 | A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2. | Entailment | [
0,
5,
13,
18
] | [] | {'Clinical Trial ID': 'NCT00828074', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level 1 - Vinorelbine at 20mg/m^2', ' Vinorelbine at 20mg/m^2 weekly intravenous (I.V.) on days 1, 8, 15 and sorafenib 200 mg given orally (p.o.) twice daily for 28 days', 'INTERVENTION 2: ', ' Phase I: Dose Level 2 - Vinorelbi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 333c2723-e2e8-4c68-9591-36b7f169ff26 | |
Single | Results | NCT00477464 | 59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00477464', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib 1250 mg and Capecitabine 2000 mg/m^2', ' Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1fa01b9a-1288-404c-ad58-8dcf3db3264c | |
Comparison | Adverse Events | NCT02049957 | NCT01506609 | There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT02049957', 'Intervention': ['INTERVENTION 1: ', ' Phase 1 (Part 1): Sapanisertib 5 mg + Exemestane', ' Sapanisertib 5 mg, unmilled active pharmaceutical ingredient (API) capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 12 cycles).', 'I... | {'Clinical Trial ID': 'NCT01506609', 'Intervention': ['INTERVENTION 1: ', ' Group 2 Placebo + Carboplatin/Paclitaxel', ' Placebo BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.', 'INTERVENTION 2: ', ' ... | ed272c3f-37a1-4db7-8990-bf226f8c9822 |
Single | Results | NCT01421017 | the primary trial studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS), 9 weeks after the start of treatment. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01421017', 'Intervention': ['INTERVENTION 1: ', ' IMQ+RT', ' This arm has been closed as of 6/4/2014.', ' Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)', ' Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnigh... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b1497cf4-6b06-4227-b679-19e2ac5fb5c3 | |
Single | Eligibility | NCT00405938 | Patients diagnosed with intradural tumors are excluded from the primary trial. | Entailment | [
9,
10
] | [] | {'Clinical Trial ID': 'NCT00405938', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab/Anastrozole', ' Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section be... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 186d5a67-1309-4abc-b31a-de026c5b8bda | |
Single | Intervention | NCT00470847 | the primary trial participants will receive either Lapatinib, WBRT or Herceptin. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00470847', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib,Whole Brain Radiation,Herceptin', ' Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically-confirmed invasive br... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6b86f306-f989-4676-8f5e-c4c8a6aa4258 | |
Single | Results | NCT02463032 | There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT02463032', 'Intervention': ['INTERVENTION 1: ', ' GTx-024 9 mg', ' Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg', ' GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.', 'INTERVENTION 2: ', ' GT... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0e8e4a92-b104-4192-ad36-33b683f94216 | |
Comparison | Intervention | NCT00438659 | NCT01271725 | the primary trial has a topical intervention, whereas the secondary trial has both oral and IV interventions. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00438659', 'Intervention': ['INTERVENTION 1: ', ' Mometasone', ' Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.', 'INTERVENTION 2: ', ' Placebo', ' Patients apply 2.5 mL of an identical-appear... | {'Clinical Trial ID': 'NCT01271725', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Monotherapy', ' Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Pati... | 47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12 |
Single | Results | NCT00171704 | All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00171704', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' 2.5 mg once daily (q.d.)orally for 5 years', 'INTERVENTION 2: ', ' Tam-Let', ' 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.'], 'Eligibility': ['Inclusion Criteria',... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 03a8a787-2bf3-43e5-9c9e-7bd9c3278751 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.